Krystal Biotech (KRYS) Gross Profit (2023 - 2026)

Krystal Biotech's Gross Profit history runs 4 years deep, the most recent figure standing at $110.0 million for Q1 2026.

• In Q1 2026, Gross Profit rose 32.32% year-over-year to $110.0 million; the TTM figure through Mar 2026 stood at $392.9 million (up 26.43% YoY), while the FY2025 annual figure was $366.1 million, up 35.35% from the prior year.
• Gross Profit came in at $110.0 million for Q1 2026 at Krystal Biotech, up from $100.5 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $110.0 million in Q1 2026 to a low of $8.3 million in Q3 2023.
• A 4-year average of $72.2 million and a median of $83.2 million in 2025 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit surged 825.92% in 2024 and climbed 16.64% in 2025, its largest moves.
• Krystal Biotech's Gross Profit stood at $39.3 million in 2023, then surged by 119.41% to $86.2 million in 2024, then gained by 16.64% to $100.5 million in 2025, then increased by 9.48% to $110.0 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $110.0 million, $100.5 million, and $93.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison